Physician

Guilherme H Oliveira, MD

According to 2025 Medicare claims, Guilherme Oliveira, MD (NPI: 1699879098) practices advanced heart failure and transplant cardiology in the Tampa, FL market, with the plurality of this provider's patient population coming from Hillsborough, FL. This provider's primary affiliated billing organization is TAMPA GENERAL MEDICAL GROUP INC (NPI: 1043557853; TIN: 274749421) and primary practice location at 33606-3601. Oliveira is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Oliveira's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 268 traditional Medicare patients, billed 635 HCPCS/CPT codes, and received $44,943 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,877 prescription claims across 280 beneficiaries totaling $2,347,272 in drug costs, led by Vyndamax (Tafamidis). DME data shows 83 claims. Open Payments data shows 9 records totaling $1,653. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $67,169 to $44,943. In contrast, Part D prescription costs have moved sharply higher in recent years, from $121,985 to $2,347,272. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $4,561 and ending at $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	253	714	$67,169
2016	253	674	$47,348
2017	260	714	$60,841
2018	298	684	$57,324
2019	242	635	$52,515
2020	104	245	$31,860
2021	154	386	$41,413
2022	183	404	$37,465
2023	170	339	$32,289
2024	268	635	$44,943

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	164	1,862	$121,985
2016	246	2,525	$162,842
2017	266	3,085	$252,698
2018	299	3,582	$359,110
2019	297	3,581	$1,585,338
2020	165	967	$782,727
2021	78	682	$507,530
2022	203	1,570	$1,378,216
2023	217	1,917	$1,283,130
2024	280	2,877	$2,347,272

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	43	$5,512
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	62	$3,178
2019	N/R	119	$8,421
2020	N/R	N/R	N/R
2021	N/R	59	$7,608
2022	N/R	23	$949
2023	N/R	N/R	N/R
2024	N/R	83	$1,924

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	57	68	$109
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	30	73	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	140	249	$73
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	21	21	$48
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	99	109	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	22	660	$458,506
Entresto	Sacubitril/Valsartan	327	20,258	$421,705
Farxiga	Dapagliflozin Propanediol	326	21,270	$390,979
Vyndaqel	Tafamidis Meglumine	16	480	$335,542
Repatha Sureclick	Evolocumab	106	7,224	$137,366

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7520	Sirolimus, oral, 1 mg	N	N/R	15	$781
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	20	$409
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	29	$376
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	19	$358

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$1,653	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Guilherme H. Oliveira, MD?

Tedicare shows public-source Medicare data for Guilherme H. Oliveira, MD (NPI 1699879098), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Guilherme H. Oliveira, MD have ACO affiliation data?

Guilherme H. Oliveira, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Guilherme H. Oliveira, MD?

Guilherme H. Oliveira, MD is linked to TAMPA GENERAL MEDICAL GROUP INC (billing NPI 1043557853) in the available physician profile data.

Does Guilherme H. Oliveira, MD have Open Payments data?

Guilherme H. Oliveira, MD has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.